Evidence map›Paper›PMID 20568084›Full record

ArticleJournal of tissue engineering and regenerative medicine2010

Lentiviral shRNA knock-down of ADAMTS-5 and -9 restores matrix deposition in 3D chondrocyte culture.

Teresa C Coughlan, Aileen Crawford, Mary B Goldring, Paul V Hatton, Michael D Barker

Open access · greenAbstract read
In one paragraph

Article in Journal of tissue engineering and regenerative medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Teresa C CoughlanDepartment of Infection and Immunity, University of Sheffield Medical School, UK. teresa.c.coughlan@nottingham.ac.uk
Aileen Crawford
Mary B Goldring
Paul V Hatton
Michael D Barker
University of Sheffield · GBCornell University · US

Funding

Role of ESE1 Regulation of Type II Collagen in CartilageR01AG022021 · NIA · HOSPITAL FOR SPECIAL SURGERY · PI GOLDRING, MARY B · 2002 to 2014
$3.4M
Biotechnology and Biological Sciences Research Council BB/E013791/1NIA NIH HHS R01 AG022021NIA NIH HHS R01-AG022021
6 · The paper itself

Abstract

Aggrecan is one of the two major constituents of articular cartilage, and during diseases such as osteoarthritis (OA) it is subject to degradation by proteolytic enzymes. The primary proteases responsible for aggrecan cleavage are the aggrecanases, identified as members of the ADAMTS family of proteases, which are upregulated in response to inflammatory stimuli. It is uncertain which of the six aggrecanases (ADAMTS-1, -4, -5, -8, -9 and -15) are primarily responsible for the degradation of aggrecan in human cartilage. Here we show that four of the six aggrecanases are expressed in immortalized chondrocyte cell-lines and can be upregulated in response to inflammatory cytokines. Using RNA interference, we demonstrate robust knock-down of ADAMTS-5 and -9 expression in these cells and, by culturing them on three-dimensional (3D) scaffolds, show that reduction in expression of ADAMTS-5 enzyme results in an increase in matrix deposition. These data suggest that the quality of tissue-engineered cartilage matrix might be improved by targeted depletion of aggrecanase expression. Moreover, this work also provides further evidence that ADAMTS-5 may be a therapeutic target in the treatment of arthritic disease.

Indexed as

Gene Knockdown TechniquesADAM ProteinsADAMTS5 ProteinADAMTS9 ProteinCell LineCell Line, TransformedCells, CulturedChondrocytesExtracellular MatrixGene Expression Regulation, EnzymologicGlycosaminoglycansHumansLentivirusRNA, MessengerRNA, Small InterferingTissue ScaffoldsADAM ProteinsADAMTS5 ProteinADAMTS5 protein, humanADAMTS9 ProteinADAMTS9 protein, humanGlycosaminoglycansRNA, MessengerRNA, Small Interfering

Identifiers

PMID20568084
PMCPMC2988096
OpenAlexW2110141676

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.